<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>14(1)</volume><submitter>Luo P</submitter><pubmed_abstract>Borayflo Haemostatic matrix is a new absorbable hemostatic gelatin matrix which can be used for intraoperative assisted hemostasis. In a prospective, multicenter, non-inferiority, randomized controlled trial, a total of 354 subjects were recruited from the departments of hepatobiliary surgery, obstetrics and gynaecology and orthopaedics of 4 hospitals and randomly allocated to test group (Borayflo Haemostatic matrix) or control group (Surgiflo Haemostatic matrix) in a 1:1 ratio. In the modified intention-to-treat population, 163 (93.14%) of 175 subjects in the test group versus 167 (94.89%) of 176 subjects in the control group successfully achieved hemostasis within 5 min (P > 0.05). Non-inferiority for effective rates of hemostasis at 5 min to Surgiflo Haemostatic matrix was shown in the </pubmed_abstract><journal>Scientific reports</journal><pagination>27324</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11550802</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Efficacy and safety evaluation of a novel hemostatic gelatin matrix for intraoperative hemostasis: a prospective, randomized controlled trial.</pubmed_title><pmcid>PMC11550802</pmcid><pubmed_authors>Xu L</pubmed_authors><pubmed_authors>Yang Z</pubmed_authors><pubmed_authors>Luo P</pubmed_authors><pubmed_authors>Chen Z</pubmed_authors><pubmed_authors>Lai Q</pubmed_authors><pubmed_authors>Yi P</pubmed_authors><pubmed_authors>Guo R</pubmed_authors><pubmed_authors>Zhang B</pubmed_authors><pubmed_authors>Xie B</pubmed_authors></additional><is_claimable>false</is_claimable><name>Efficacy and safety evaluation of a novel hemostatic gelatin matrix for intraoperative hemostasis: a prospective, randomized controlled trial.</name><description>Borayflo Haemostatic matrix is a new absorbable hemostatic gelatin matrix which can be used for intraoperative assisted hemostasis. In a prospective, multicenter, non-inferiority, randomized controlled trial, a total of 354 subjects were recruited from the departments of hepatobiliary surgery, obstetrics and gynaecology and orthopaedics of 4 hospitals and randomly allocated to test group (Borayflo Haemostatic matrix) or control group (Surgiflo Haemostatic matrix) in a 1:1 ratio. In the modified intention-to-treat population, 163 (93.14%) of 175 subjects in the test group versus 167 (94.89%) of 176 subjects in the control group successfully achieved hemostasis within 5 min (P > 0.05). Non-inferiority for effective rates of hemostasis at 5 min to Surgiflo Haemostatic matrix was shown in the </description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Nov</publication><modification>2025-04-04T00:32:39.834Z</modification><creation>2025-04-04T00:32:39.834Z</creation></dates><accession>S-EPMC11550802</accession><cross_references><pubmed>39521848</pubmed><doi>10.1038/s41598-024-77487-3</doi></cross_references></HashMap>